title: In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci.
abstract: Infections caused by coagulase-negative staphylococci are becoming increasingly important, particularly those of nosocomial origin, as the organisms are frequently multi-resistant. New antimicrobial strategies are needed. The bactericidal activity of a combination of cefpirome with either vancomycin or teicoplanin against 12 strains of methicillin-resistant staphylococci with a decreased susceptibility to teicoplanin was determined in vitro by a time killing method. Strains Mu3 and Mu50 of Staphylococcus aureus were also studied. Cefpirome (0.125-0.5 x MIC) combined with vancomycin (0.25-1 x MIC) or teicoplanin (0.125-1 x MIC) acted synergically against 12 isolates over 18 h in most cases. A synergistic killing effect was also observed with the Mu3 and Mu50 strains of glycopeptide-intermediate S. aureus but over a longer period.
authors.affiliation: Service Microbiologie, Hôpital Saint Vincent de Paul, 82, Avenue Denfert Rochereau 75014, Université Paris V, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Bergeret
authors.forename: N
authors.initials: N
authors.lastname: Boutros
authors.forename: J
authors.initials: J
authors.lastname: Raymond
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D006020:Glycopeptides; D006801:Humans; D066298:In Vitro Techniques; D010068:Oxacillin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000302:isolation & purification; D041162:Staphylococcus haemolyticus / Q000187:drug effects* / Q000302:isolation & purification; D000097572:Cefpirome
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D006020:Glycopeptides; D010068:Oxacillin; D000097572:Cefpirome